Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Mathew Clement, Research Fellow at the School of Medicine, Cardiff University

Glioblastoma: why immunotherapy may offer hope for brain cancer patients

Glioblastoma is one of the most poorly survived cancers. April stock/Shutterstock

Glioblastoma is the most common and deadliest form of brain cancer. Patients face a bleak prognosis – the average survival after diagnosis is between 12 and 15 months. And just 6.9% of patients survive beyond five years, making it one of the most poorly survived cancers.

The toll this cancer takes goes beyond survival rates. Patients can suffer from symptoms like headaches, seizures, cognitive and personality changes, and neurological impairments. These symptoms may drastically affect their quality of life. But despite the urgent need, no targeted treatments exist for this devastating disease.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.